Is CJC-1295 Legal in Australia? (2026 Research Status)

Imagine you’re a researcher at an Australian university. You’re designing a study on growth hormone-releasing hormone (GHRH) analogs. GHRH is a peptide that signals the pituitary to release growth hormone. You’ve identified CJC-1295 as a compound of interest.

This peptide has a unique pharmacokinetic profile — that is, a distinctive pattern of how it enters, moves through, and leaves the body. Before you can proceed, you need to answer a critical question.

Is this peptide legal to import, possess, and study in Australia?

The answer, like many regulatory questions in peptide research, is more nuanced than a simple yes or no. Australia’s therapeutic goods framework treats different peptides in different ways. The rules for research use don’t always match what you read online.

Online forums and community discussions can be misleading on this topic. In this guide, we’ll separate four common misconceptions about CJC-1295’s legal status from the regulatory reality. We’ll also point you toward the resources you need to navigate this landscape responsibly.

What Is CJC-1295?

Before diving into legality, a brief primer may be helpful. CJC-1295 is a synthetic analog of growth hormone-releasing hormone. It was designed to stimulate the pituitary gland to release growth hormone (GH).

Native GHRH is the body’s own version of this hormone. CJC-1295 stays active longer than native GHRH does. Early-phase clinical research explored how the peptide affects GH and insulin-like growth factor 1 (IGF-1) secretion in human subjects.

That early work is detailed in Teichman et al., 2006.

Two versions are often discussed in research literature. One is CJC-1295 with Drug Affinity Complex (DAC). The other is CJC-1295 without DAC, sometimes called Mod GRF 1-29.

The DAC change greatly extends the peptide’s half-life. Half-life is the time it takes for the body to clear half of a substance. DAC lets the peptide bind to albumin, a protein that floats in the blood.

This property was first characterized in preclinical work by Jetté et al., 2005. Preclinical work means research done in cells or animals, not in people. This distinction matters for both the peptide’s research uses and its regulatory classification.

For a deeper dive into the compound’s mechanism and research history, see our full CJC-1295 compound profile.

Myth #1: “CJC-1295 Is Completely Banned in Australia”

The misconception: Many researchers assume that CJC-1295 must be outright prohibited. After all, it isn’t available over the counter or through standard pharmaceutical channels.

The reality: Australia regulates therapeutic goods through the Therapeutic Goods Administration (TGA). This agency sorts substances into schedules under the Poisons Standard. A schedule sets the rules for how a substance can be sold and used.

CJC-1295 is not listed as a registered medicine on the Australian Register of Therapeutic Goods (ARTG). This means it cannot be legally marketed or sold as a therapeutic product for human use in Australia.

However, “not registered” is not the same as “banned.” Australian law allows legitimate use of unregistered substances in research contexts. Universities and licensed research institutions can often access such compounds through appropriate channels.

Those channels usually require institutional ethics approvals and import permits. Ethics approval means a review board has checked that your study treats subjects fairly.

The distinction matters. A substance’s regulatory status depends heavily on the context of its use. Context means the situation: is the substance being marketed as a medicine, used in a clinical trial, or employed in preclinical lab research?

Researchers should verify the current scheduling status directly with the TGA. Classifications can change over time.

Myth #2: “All Peptides Face the Same Legal Treatment in Australia”

The misconception: Peptides share a common biochemical category. People often assume they all face identical regulatory treatment.

The reality: Australian regulators evaluate each substance individually. Some peptides are classified as Prescription Only (Schedule 4). Others may fall under different schedules or remain unscheduled entirely.

The classification depends on several factors. These include the substance’s pharmacological activity — that is, how it acts on the body. Its history of clinical use and its potential for misuse also matter.

CJC-1295’s specific regulatory position is